Reduced intensity conditioning for hematopoietic stem cell transplantation: has it achieved all it set out to?

References

• Pasquini MC, Wang Z, Schneider L. Current use and outcome of hematopoietic stem cell transplantation: part I-CIBMTR Summary Slides, 2007. CIBMTR Newsletter [serial online]. 2007;13(2):5–9.
   Google Scholar
• Bacigalupo A, Sormani MP, Lamparelli T, Gualandi F, Occhini D, Bregante S, . Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2004;89:1238–47.
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, . Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–400.
   PubMed Web of Science ®Google Scholar
• Resnick IB, Shapira MY, Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transpl Immunol. 2005;14:207–19.
   PubMed Web of Science ®Google Scholar
• Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M, . Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol. 2003;31:941–52.
   PubMed Web of Science ®Google Scholar
• Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, . One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49:511–33.
   PubMed Web of Science ®Google Scholar
• Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, . Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med. 1983; 309:1347–53.
   PubMed Web of Science ®Google Scholar
• Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, . Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001;293: 293–7.
   PubMed Web of Science ®Google Scholar
• Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr, . Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882–91.
   PubMed Web of Science ®Google Scholar
• Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204–13.
   PubMed Web of Science ®Google Scholar
• Devine SM, Adkins DR, Khoury H, Brown RA, Vij R, Blum W, . Recent advances in allogeneic hematopoietic stem-cell transplantation. J Lab Clin Med. 2003;141:7–32.
   PubMedGoogle Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. New Engl J Med. 2006;354:1813–26.
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Kabisch H, . Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant. 2001;27:349–54.
   PubMed Web of Science ®Google Scholar
• Ferry C, Socie G. Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned? Exp Hematol. 2003;31:1182–6.
   PubMed Web of Science ®Google Scholar
• Xun C, Thompson J, Jennings C, Brown S, Widmer M. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice. Blood. 1994;83:2360–7.
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–5.
   PubMed Web of Science ®Google Scholar
• Hakim FT, Mackall CL. Graft versus host disease. New York: Marcel Dekker; 1997.
   Google Scholar
• Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, . Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–6.
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–63.
   PubMed Web of Science ®Google Scholar
• Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol. 1991;9:175–88.
   PubMed Web of Science ®Google Scholar
• Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nature Med. 1999;5:444–7.
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant. 1999;5:192–203.
   PubMedGoogle Scholar
• Mielcarek M, Storb R. Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. Cancer Treat Rev. 2003;29:283–90.
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, . Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–8.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Third EBMT/AMGEN workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant. 2004;33:691–6.
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, . Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756–62.
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymph. 2005;46:1251–60.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Traina F, Storer B, Maris M, Bethge WA, Carpenter P, . Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant. 2005;35:277–82.
   PubMedGoogle Scholar
• Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation. 2004;78:1014–20.
   PubMed Web of Science ®Google Scholar
• Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, . Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102:470–6.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, . Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103:1548–56.
   PubMed Web of Science ®Google Scholar
• Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, . Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–7.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, . Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98: 3595–9.
   PubMed Web of Science ®Google Scholar
• Johansson JE, Brune M, Ekman T. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant. 2001;28:737–42.
   PubMedGoogle Scholar
• Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Cancer. 2006;20:1661–72.
   Google Scholar
• Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, . Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550–8.
   PubMed Web of Science ®Google Scholar
• Martino R, Caballero MD, Canals C, Simon JA, Solano C, Urbano-Ispizua A, . Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001;115:653–9.
   PubMed Web of Science ®Google Scholar
• Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, . Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood. 2002;99:75–82.
   PubMed Web of Science ®Google Scholar
• Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, . Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26:577–84.
   PubMed Web of Science ®Google Scholar
• Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, . Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–46.
   PubMed Web of Science ®Google Scholar
• Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, . Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:303–6.
   PubMed Web of Science ®Google Scholar
• Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, . Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Cancer. 2009;23:1763–70.
   Google Scholar
• Bachanova V, Brunstein CG, Burns LJ, Miller JS, Luo X, Defor T, . Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant. 2009 Feb;43(3):237–44.
   PubMedGoogle Scholar
• Tomblyn M, Brunstein C, Burns LJ, Miller JS, MacMillan M, DeFor TE, . Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:538–45.
   PubMed Web of Science ®Google Scholar
• Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, . Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530–6.
   PubMed Web of Science ®Google Scholar
• Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, . Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002;8:512–20.
   PubMed Web of Science ®Google Scholar
• Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, . Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99:1978–85.
   PubMed Web of Science ®Google Scholar
• Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, . Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15:679–85.
   PubMedGoogle Scholar
• Nakamae H, Kirby KA, Sandmaier BM, Norasetthada L, Maloney DG, Maris MB, . Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15:694–703.
   PubMed Web of Science ®Google Scholar
• Mattsson J, Ringden O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:165–70.
   PubMed Web of Science ®Google Scholar
• de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, . Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865–72.
   PubMed Web of Science ®Google Scholar
• Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, . Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Am J Hematol. 2007;82:873–80.
   PubMedGoogle Scholar
• Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, . Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455–62.
   PubMed Web of Science ®Google Scholar
• Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, . Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia. 2009;23(10):1763–70.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, . Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94:230–8.
   PubMed Web of Science ®Google Scholar
• Barbot C, Rice A, Vanes I, Mahon FX, Jazwiec B, Reiffers J. Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients. Nou Rev Franc d'Hematol. 1994;36:325–31.
   PubMedGoogle Scholar
• Rice A, Reiffers J, Bernard P, Foures C, Bascans E, Lacombe F, . Incomplete stroma formation after allogeneic marrow or autologous blood stem cell transplantation. Nou Rev Franc d'Hematol. 1992;34:167–74.
   PubMedGoogle Scholar
• Rice A, Reiffers J, Bernard P, Foures C, Lacombe F, Marit G, . Long-term marrow cultures after allogeneic bone marrow transplantation. Blood. 1990;76:266–7.
   PubMedGoogle Scholar
• Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M, . Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol. 2007;138:517–26.
   PubMed Web of Science ®Google Scholar
• Shaw BE, Byrne JL, Das-Gupta E, Carter GI, Russell NH. The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. Biol Blood Marrow Transplant. 2007;13:550–9.
   PubMed Web of Science ®Google Scholar
• Ting DT, Spitzer TR, Chaudhary A, Muzikansky A, Colby C, Power K, . Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant. 2008;42:329–35.
   PubMedGoogle Scholar
• Reisner Y, Martelli MF. From ‘megadose’ haploidentical hematopoietic stem cell transplants in acute leukemia to tolerance induction in organ transplantation. Blood Cell Mol Dis. 2008;40:1–7.
   PubMedGoogle Scholar
• Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, . Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139:70–80.
   PubMed Web of Science ®Google Scholar
• Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N, . Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003;9:320–9.
   PubMed Web of Science ®Google Scholar
• Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB, . Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004;104:2254–62.
   PubMed Web of Science ®Google Scholar
• Michallet AS, Furst S, Le QH, Dubois V, Praire A, Nicolini F, . Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens. Br J Haematol. 2005;128:676–89.
   PubMedGoogle Scholar
• Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica. 2007;92: 1004–6.
   PubMedGoogle Scholar
• Boeck S, Hamann M, Pihusch V, Heller T, Diem H, Rolf B, . Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant. 2006;37:57–64.
   PubMedGoogle Scholar
• Saito B, Fukuda T, Yokoyama H, Kurosawa S, Takahashi T, Fuji S, . Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol Blood Marrow Transplant. 2008;14: 1148–55.
   PubMed Web of Science ®Google Scholar
• Reddy V, Iturraspe JA, Tzolas AC, Meier-Kriesche HU, Schold J, Wingard JR. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood. 2004;103: 4330–5.
   PubMed Web of Science ®Google Scholar
• Talarn C, Urbano-Ispizua A, Martino R, Perez-Simon JA, Batlle M, Herrera C, . Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome. Haematologica. 2007;92:1655–63.
   PubMedGoogle Scholar
• Collin MP, Hart DN, Jackson GH, Cook G, Cavet J, Mackinnon S, . The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med. 2006; 203:27–33.
   PubMed Web of Science ®Google Scholar
• Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FC, Blume KG, . Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood. 2002;99:1442–8.
   PubMed Web of Science ®Google Scholar
• Mohty M, Gaugler B, Faucher C, Sainty D, Lafage-Pochitaloff M, Vey N, . Recovery of lymphocyte and dendritic cell subsets following reduced intensity allogeneic bone marrow transplantation. Hematology (Amsterdam). 2002;7:157–64.
   PubMedGoogle Scholar
• Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, . A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464–72.
   PubMed Web of Science ®Google Scholar
• Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, . Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024–30.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, . Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303–14.
   PubMed Web of Science ®Google Scholar
• Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, . Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062–8.
   PubMed Web of Science ®Google Scholar
• Ringden O, Le Blanc K. Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. Apmis. 2005;113:813–30.
   PubMed Web of Science ®Google Scholar
• Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, . Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95:3702–9.
   PubMed Web of Science ®Google Scholar
• McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, . Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years’ experience of the national marrow donor program. Blood. 2000;95: 2219–25.
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, . Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. New Engl J Med. 2001;344:175–81.
   PubMed Web of Science ®Google Scholar
• Xun CQ, Tsuchida M, Thompson JS. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation. 1997;64:297–302.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant. 1991;7:193–8.
   PubMed Web of Science ®Google Scholar
• Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964–8.
   PubMed Web of Science ®Google Scholar
• Schwaighofer H, Kernan NA, O'Reilly RJ, Brankova J, Nachbaur D, Herold M, . Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation: influence of conditioning and hematopoietic reconstitution. Transplantation. 1996;62:947–53.
   PubMed Web of Science ®Google Scholar
• Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754–9.
   PubMed Web of Science ®Google Scholar
• Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, . Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285: 412–5.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Louboutin JP, Zhu J, Rivera AJ, Emerson SG. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest. 2002;109:1335–44.
   PubMed Web of Science ®Google Scholar
• Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood. 2002;99: 2586–91.
   PubMed Web of Science ®Google Scholar
• Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, . Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Med. 2002;8: 575–81.
   PubMed Web of Science ®Google Scholar
• Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, . Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172: 7393–8.
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Diez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, . Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol. 2005;130:394–403.
   PubMed Web of Science ®Google Scholar
• Sala-Torra O, Martin PJ, Storer B, Traina F, Sorror ML, Storb R, . Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant. 2008;41:887–93.
   PubMedGoogle Scholar
• Remberger M, Mattsson J, Hassan Z, Karlsson N, LeBlanc K, Omazic B, . Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. Bone Marrow Transplant. 2008;41:399–405.
   PubMedGoogle Scholar
• Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.
   PubMed Web of Science ®Google Scholar
• Socie G. The NIH consensus criteria for chronic graft-versus-host disease: far more than just another classification. Cancer. 2009;23:1–2.
   Google Scholar
• Truitt RL. The Mortimer M. Bortin Lecture: to destroy by the reaction of immunity: the search for separation of graft-versus-leukemia and graft-versus-host. Biol Blood Marrow Transplant. 2004;10:505–23.
   PubMedGoogle Scholar
• Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS, . Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:1083–94.
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, . Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.
   PubMed Web of Science ®Google Scholar
• Kolb H-J, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767–76.
   PubMed Web of Science ®Google Scholar
• Kroger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, . Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2004;10: 698–708.
   PubMed Web of Science ®Google Scholar
• Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, . Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106:2969–76.
   PubMed Web of Science ®Google Scholar
• Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, . Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer. 2005; 104:1931–8.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, . 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, . Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. New Engl J Med. 1989;321:1174–8.
   PubMed Web of Science ®Google Scholar
• Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002;8: 257–60.
   PubMed Web of Science ®Google Scholar
• Ballen KK. New trends in umbilical cord blood transplantation. Blood. 2005;105:3786–92.
   PubMed Web of Science ®Google Scholar
• Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, . Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. New Engl J Med. 2000;342:1846–54.
   PubMed Web of Science ®Google Scholar
• Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, . Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369: 1947–54.
   PubMed Web of Science ®Google Scholar
• Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, . Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. New Engl J Med. 2004;351:2265–75.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, . Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. New Engl J Med. 1997;337:373–81.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Brunstein CG, Wagner JE. Double umbilical cord blood transplantation. Curr Opin Immunol. 2006;18: 571–5.
   PubMed Web of Science ®Google Scholar
• Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009; 147:262–74.
   PubMed Web of Science ®Google Scholar
• Matsuno N, Wake A, Uchida N, Ishiwata K, Araoka H, Takagi S, . Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. Blood. 2009;114: 1689–95.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Rocha V, Ionescu I, Bierings M, Harris RE, Wagner J, . Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant. 2007;13: 1073–82.
   PubMed Web of Science ®Google Scholar
• Nabhan S, Rocha V, Arcese W, Sirvent A, Ionescu I, Bizzetto R, . Influence of myeloablative conditioning regimens on outcomes after single unrelated cord blood transplantation for adults with leukemia: an analysis on behalf of Eurocord-EBMT-Netcord. ASH Annual Meeting Abstracts. Blood. 2008;112:115.
   Google Scholar
• Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, . Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110:3064–70.
   PubMed Web of Science ®Google Scholar
• Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, . Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13:82–9.
   PubMed Web of Science ®Google Scholar
• Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli MF. Haploidentical stem cell transplantation in leukemia. Blood Rev. 2001;15:111–9.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, . Successful engraftment of T-cell-depleted haploidentical ‘three-loci’ incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84:3948–55.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, . Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J Med. 1998;339: 1186–93.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, . Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007;25:690–7.
   PubMed Web of Science ®Google Scholar
• Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, . Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113:4771–9.
   PubMed Web of Science ®Google Scholar
• Barfield RC, Otto M, Houston J, Holladay M, Geiger T, Martin J, . A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy. 2004;6:1–6.
   PubMed Web of Science ®Google Scholar
• Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M, . Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol. 2006;34:1746–52.
   PubMed Web of Science ®Google Scholar
• Bethge WA, Faul C, Bornhauser M, Stuhler G, Beelen DW, Lang P, . Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cell Mol Dis. 2008;40:13–9.
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, . HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14: 641–50.
   PubMed Web of Science ®Google Scholar
• Aversa F, Reisner Y, Martelli MF. The haploidentical option for high-risk haematological malignancies. Blood Cell Mol Dis. 2008;40:8–12.
   PubMed Web of Science ®Google Scholar
• Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A, . Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106:4397–406.
   PubMed Web of Science ®Google Scholar
• Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, . Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant. 1999;5:133–43.
   PubMedGoogle Scholar
• Petrus MJ, Williams JF, Eckhaus MA, Gress RE, Fowler DH. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant. 2000;6:182–9.
   PubMed Web of Science ®Google Scholar
• Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–64.
   PubMed Web of Science ®Google Scholar
• Weiss L, Abdul-Hai A, Or R, Amir G, Polliack A. Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia. Bone Marrow Transplant. 2003;31:11–5.
   PubMedGoogle Scholar
• Zoller M. Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablatively conditioned tumor-bearing murine host. J Immunol. 2003;171:6941–53.
   PubMed Web of Science ®Google Scholar
• Pan Y, Luo B, Sozen H, Kalscheuer H, Blazar BR, Sutherland DE, . Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy. Transplantation. 2003;76:216–24.
   PubMedGoogle Scholar
• Bethge WA, Hegenbart U, Stuart MJ, Storer BE, Maris MB, Flowers MED, . Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood. 2004;103:790–5.
   PubMed Web of Science ®Google Scholar
• Mapara MY, Pelot M, Zhao G, Swenson K, Pearson D, Sykes M. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol Blood Marrow Transplant. 2001;7:646–55.
   PubMed Web of Science ®Google Scholar
• Kim YM, Mapara MY, Down JD, Johnson KW, Boisgerault F, Akiyama Y, . Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning. Blood. 2004;103:732–9.
   PubMedGoogle Scholar
• Hirshfeld E, Weiss L, Kasir J, Zeira M, Slavin S, Shapira MY. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation? Bone Marrow Transplant. 2006;38:359–64.
   PubMedGoogle Scholar
• Turner BE, Kambouris ME, Sinfield L, Lange J, Burns AM, Lourie R, . Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Transplantation. 2008;86:968–76.
   PubMedGoogle Scholar
• Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, . Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008;111:2470–5.
   PubMed Web of Science ®Google Scholar
• Wilson J, Cullup H, Lourie R, Sheng Y, Palkova A, Radford KJ, . Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med. 2009;206:387–98.
   PubMedGoogle Scholar
• Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, . HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–30.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, . In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–25.
   PubMed Web of Science ®Google Scholar
• Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant. 2003;9:453–9.
   PubMedGoogle Scholar
• O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, . Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.
   PubMed Web of Science ®Google Scholar
• Wasch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R, . Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant. 2000;26:243–50.
   PubMed Web of Science ®Google Scholar
• Cull GM, Haynes AP, Byrne JL, Carter GI, Miflin G, Rebello P, . Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol. 2000;108: 754–60.
   PubMed Web of Science ®Google Scholar
• Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, . Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616–23.
   PubMed Web of Science ®Google Scholar